Search Results for “ breast cancer ” – media

A “dark horse” has emerged in breast cancer treatment

The birth of blockbuster drugs in the field of breast cancer is not new. After all, there is fertile soil for the birth of big drugs here. The most core factor is the extremely large patient population. Breast cancer is one of the most common cancers and one of the leading causes of cancer-related deaths worldwide. In 2020, more than 2 million patients were diagnosed with breast cancer. In the United States, more than 290,000 patients are expected to be diagnosed in 2023. And the proportion of important subtypes is not low. For example, HR+ breast cancer is the most common breast cancer subtype, and more than 65% of breast cancer tumors are considered to be HR+/HER2 low expression or negative. Therefore, a strong demand for drugs has been created. The growth of HR+ breast cancer cells is usually driven by estrogen receptors (ER). Endocrine therapy for ER-driven diseases is ...
- Source: drugdu
- 36
- November 19, 2024
Computational Tool Integrates Transcriptomic Data for Improved Breast Cancer Diagnosis and Treatment

Breast cancer is the most commonly diagnosed cancer globally, presenting in various subtypes that require precise identification for effective, personalized treatment. Traditionally, cancer subtyping has been conducted through histological staining (immunohistochemistry), which involves identifying specific markers that categorize tumors into distinct subtypes. Recently, high-throughput transcriptomic profiling has transformed the way breast cancer subtypes are identified by analyzing gene activity in cancer cells through the total messenger RNAs present, which correspond to gene sequences and are used by ribosomes to synthesize proteins. Transcriptomic profiling utilizes RNA sequencing (RNAseq), a rapidly evolving molecular biology technique that sequences RNA strands efficiently. As RNA sequencing becomes more affordable, it holds the potential for routine clinical integration to aid in diagnosis and treatment decisions. However, its application is currently limited by the requirement for processing large sample batches simultaneously and difficulties in comparing samples across different platforms. Now, scientists have developed a computational tool that ...
- Source: drugdu
- 77
- July 24, 2024
Hengrui Pharmaceuticals’ Innovative Drug Dalsili, HRS-1358 Combination for Breast Cancer Approved for Clinical Trial

Recently, Hengrui Pharmaceuticals and its subsidiary Shandong Shengdi Pharmaceutical Co., Ltd. received the Notice of Approval for Clinical Trial of Drugs approved by the State Drug Administration, approving the company’s novel and highly selective CDK4/6 inhibitor, dalsiril hydroxyethanesulfonate tablets, combined with HRS-1358 tablets to carry out a clinical trial for breast cancer. Breast cancer is the number one malignant tumor affecting women worldwide. According to the Global Cancer Epidemiology Report 2024, the incidence and mortality rates of breast cancer rank first among female malignant tumors, with approximately 2.31 million new cases of breast cancer and 670,000 deaths globally each year, ranking first in terms of incidence and mortality rates of female malignant tumors [1]. In recent years, the incidence and mortality rates of breast cancer have shown a continuous upward trend in China, and it ranks fourth among the causes of cancer death. HRS-1358 is a novel, highly efficient and ...
- Source: drugdu
- 81
- July 24, 2024
Hinova Pharmaceuticals receives FDA Fast Track Designation for HP518 for Treatment of AR+ Triple-Negative Breast Cancer (TNBC)

CHENGDU, China, July 5, 2024 /PRNewswire/ — Hinova Pharmaceuticals Inc. (688302.SH), a leading biopharmaceutical company dedicated to developing innovative cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for HP518, an investigational drug for the treatment of Androgen-receptor positive (AR+) triple-negative breast cancer (TNBC). This designation is intended to expedite the development and review process for drugs that address serious conditions and fill an unmet medical need. About HP518 HP518 is a potent PROTAC AR degrader showing efficacy in AR+ TNBC. In preclinical IND-enabling studies, HP518 has demonstrated promising antitumor activity in AR+ TNBC animal models, showcasing significant tumor reduction and a favorable safety profile. The molecular subforms of TNBC are particularly aggressive forms of breast cancer that lack targeted treatment options, accounting for approximately 15-20% of all breast cancer cases, and are characterized by the absence of estrogen and progesterone receptors ...
- Source: drugdu
- 68
- July 9, 2024
ICL granted £150,000 to explore link between breast cancer and breastfeeding

Breast cancer is the most common cancer in the UK, accounting for 15% of all cancersImperial College London (ICL) researchers have been awarded £150,715 by Breast Cancer Now to investigate the links between breast cancer and breastfeeding in women.Currently the most common cancer in the UK, breast cancer affects around 55,000 women every year and accounts for 15% of all cancer cases in the UK. The disease occurs when abnormal breast cells grow out of control and form tumours. Previous research has already shown that breastfeeding is linked to a lower risk of developing breast cancer. Data analysis has shown that the risk of developing the disease decreases by 4% for every 12 months of breastfeeding. Researchers have estimated that this is due to breastfeeding altering the balance of hormones in the body, protecting breast cells and making them less vulnerable to changes that cause cancer. In addition, ICL researchers ...
- Source: drugdu
- 70
- July 3, 2024
New AI-System Detects Breast Cancer with Almost 100% Accuracy

Breast cancer represents 30% of all new cancer diagnoses in women annually, with projections from the American Cancer Society indicating that 42,500 women will succumb to the disease in 2024. Researchers have now developed a new artificial intelligence (AI) architecture capable of detecting breast cancer with a remarkable 99.72% accuracy, demonstrating the potential to redefine digital pathology. This development follows a previous initiative by the same research team at Northeastern University (Boston, MA, USA) which launched a web-based AI application aimed at diagnosing prostate cancer more efficiently and accurately. These projects are part of a broader effort to establish an online platform that allows physicians to utilize advanced AI techniques for diagnosing various cancers. For the breast cancer project, the research team utilized the publicly accessible Breast Cancer Histopathological Database, which includes images of both malignant and benign breast tissues. Leveraging this resource, they built an ensemble deep learning model ...
- Source: drugdu
- 104
- June 29, 2024
Genetic associations of key genes in breast cancer pathogenesis

Background and objectives Breast cancer remains a significant global health concern, warranting further exploration into its genetic basis and potential therapeutic targets. This study aimed to elucidate the genetic associations of seven pivotal genes with breast cancer and discern their potential role in disease prognosis. Methods The genes VEGFA, BRCA1, RAD51, CCNB1, CHEK1, CDK1, and XRCC4 were curated from over 30 articles. Their association with breast cancer was analyzed using both in silico and in vitro techniques. The in silico assessment involved constructing a protein-protein interaction network, accompanied by Gene Ontology and pathway enrichment analysis. Further, survival and expression analysis were conducted using Kaplan-Meier Plotter and the UALCAN database respectively. At the protein level, expression was observed using the Human Protein Atlas database. The in vitro validation involved analyzing mRNA expression levels in 10 breast cancer tissue samples. Results The study revealed that all seven genes are significantly upregulated in ...
- Source: drugdu
- 80
- May 2, 2024
IceCure submits final breast cancer cryoablation data to FDA

BY SEAN WHOOLEYIceCure Medical (Nasdaq:ICCM) announced today that it submitted final data to the FDA requesting marketing authorization for its ProSense system. Caesarea, Israel-based IceCure designed ProSense to deliver cryoablation that treats breast cancer in a 20-40-minute outpatient procedure. It seeks FDA authorization for treating patients with early-stage T1 invasive breast cancer with cryoablation and adjuvant hormone therapy. ProSense already holds FDA breakthrough device designation and has clearance in the U.S. for other indications. Those include treating benign tumors of the breast, and tumors in the kidney and liver. However, the FDA in 2022 denied IceCure’s de novo classification request for ProSense to treat patients with early-stage, low-risk breast cancer. In January of this year, the FDA agreed to reopen the de novo file. An affirmative response from the FDA provided IceCure with a potential pathway to clearance. The company submitted a five-year follow-up dataset from the ICE3 study and ...
- Source: drugdu
- 110
- April 22, 2024
Hengrui Pharmaceuticals Class 1 New Drug HRS8807 for ER-positive, HER2-negative Breast Cancer Combination Treatment Approved for Clinical Trial

Recently, Hengrui Pharmaceuticals and its subsidiary Shanghai Hengrui Pharmaceuticals Co., Ltd. received a Notice of Approval of Drug Clinical Trial from the State Drug Administration, approving the company to conduct an open, multi-center Phase I clinical study on the safety, tolerability and pharmacokinetics of HRS8807 combined with dalsylate hydroxyethanesulfonate in ER-positive, HER2-negative metastatic or locally advanced breast cancer patients. Breast cancer is the most common malignant tumor worldwide. According to the Global Cancer Epidemiology Report 2024, breast cancer ranks first among female malignant tumors in terms of incidence and mortality, with approximately 2.31 million new cases of breast cancer and 670,000 deaths per year globally, ranking first in terms of incidence and mortality of female malignant tumors. Among all breast cancer patients, about 70% are ER-positive, and the guideline-recommended standard treatment is endocrine drugs combined with CDK4/6 inhibitors. In contrast, the new generation of oral selective estrogen receptor down-regulators (SERDs) ...
- Source: drugdu
- 82
- April 20, 2024
Hengrui’s Innovative Drug Fluzoparib Alone or in Combination with Apatinib HER2 Negative Breast Cancer Indication Included in Breakthrough Therapy Variety

Recently, Hengrui Pharmaceuticals’ innovative drug fluazoparib (Errayi®) alone or in combination with apatinib (Etan®) for the treatment of HER2-negative breast cancer with mutations in the germline breast cancer susceptibility gene (gBRCA) has been included in the list of breakthrough therapeutic varieties by the Center for Drug Evaluation of the State Drug Administration (CDEA). According to the data released by the International Agency for Research on Cancer (IARC) of the World Health Organization in 2020, breast cancer has become the world’s number one malignant tumor and is one of the most common malignant tumors in women. Currently, the incidence of breast cancer in domestic patients is growing rapidly and has been ranked first on the spectrum of female tumor incidence, and recurrence and metastasis occur in nearly 50% of patients after treatment. Human breast cancer susceptibility genes (BRCA) are important oncogenes in the human body, including BRCA1 and BRCA2. Compared with ...
- Source: drugdu
- 138
- April 8, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.